Tissue Regenix announced that it has signed an exclusive distribution agreement with Australian Allografts for the distribution of the Tissue Regenix OrthoPure® XT product in Australia and New Zealand. This is subject to regulatory approval from the Therapeutic Goods Administration ('TGA'). As part of the agreement, Australian Allografts and Tissue Regenix are mutually committed to achieving the TGA regulatory approval process to enable the import and distribution of the products.

The initial distribution agreement is for three years and requires Australian Allografts to purchase a minimum unit volume each year after achieving the TGA approval. The OrthoPure® XT decellularised xenograft ligament utilises Tissue Regenix's patented dCELL® technology and is the only available, non-human biologic graft for certain anterior cruciate ligament ('ACL') reconstruction procedures on the market. OrthoPure® XT can also be used in the reconstruction of other knee ligaments, including multi-ligament and primary procedures when an autograft is not an option.